Q: In the treatment of AECOPD, we sometimes encounter the combination of other drugs, are there any interactions between quinolones and other therapeutic drugs and how do they interact? In addition, when treating AECOPD, it is very important for patients to accurately grasp the timing of antimicrobial drugs, how do you choose and accurately grasp the timing of treatment based on your years of practical experience? Generally speaking, there may be interactions between quinolones and some drugs, such as theophylline, warfarin, digoxin, morphine, oral contraceptives, probenecid, ranitidine, eugenol, calcium, iron, and acid suppressants. In the treatment of AECOPD, the most common drug combination encountered is theophylline, whose interaction is that theophylline concentration may increase due to competition for excretion when combined with theophylline, and the dosage of theophylline should be reduced at this time. It has been reported that the new quinolones listed in recent years have reduced interactions, especially with theophylline without interactions. To accurately grasp the selection and timing of antimicrobial drug use, we must first clarify what is AECOPD and what are the main causes of acute exacerbation of COPD? The ATS/ERS guidelines for COPD 2004 state that AECOPD is an event in the natural course of the disease characterized by changes in dyspnea, cough and/or sputum beyond the daily baseline state, requiring adjustments in therapy. Our COPD guidelines also mention that AECOPD refers to a short-term increase in cough, sputum, shortness of breath or (and) wheezing, increased sputum volume, purulent or mucopurulent, and may be accompanied by a significant increase in inflammation such as fever during the course of the disease. Domestic and international guidelines and a large amount of clinical research literature mention that the main cause of acute exacerbation of COPD is bacterial infection, and antimicrobial drugs are one of the important treatments for AECOPD; for patients with AECOPD, anti-infective treatment has an important status, and the indication for choosing antimicrobial drug treatment is the presence of purulent sputum and a significant increase in sputum volume in patients. Q: Hello expert, please introduce the current status of bacterial resistance in China and some major issues that should be considered in antibiotic selection, taking into account your actual clinical experience. Most studies have shown that Streptococcus pneumoniae is the most common pathogen of community-acquired lower respiratory tract infections. Several studies have also found that community-acquired lower respiratory tract infections can be caused by a mixture of bacterial and atypical pathogens, including multiple bacterial infections or a mixture of bacteria and viruses. Data show that the incidence of co-infection with atypical pathogens ranges from 3-40%;. Domestic data also confirm that in recent years, infections with atypical pathogens have increased significantly in community-acquired lower respiratory tract infections, occupying a very important position. The rate of non-susceptibility of Streptococcus pneumoniae to penicillin (including intermediaries and drug resistance) in adults with community-acquired lower respiratory tract infections in China is around 50%. The rate of penicillin resistance of Streptococcus pneumoniae is increasing, and further application will induce an increase in resistance. From the perspective of rotating the use of antibiotics, clinicians should consider the use of other drugs. In China, the resistance of Streptococcus pneumoniae to macrolides is very common, with a resistance rate of about 80% and a high level of resistance, so it is no longer appropriate to continue using macrolide antibiotics to treat infections caused by Streptococcus pneumoniae. However, macrolides have good efficacy in atypical pathogenic infections. Streptococcus pneumoniae has a low resistance rate to the new generation of fluoroquinolones and remains effective against Streptococcus pneumoniae resistant to penicillin and macrolide antibiotics. There is a gradual convergence of various guideline provisions, implementation of which improves prognosis, and selection of treatment regimens that comprehensively cover typical and atypical pathogens is consistent with the guidelines. Quinolones are ideal for the treatment of patients with community-acquired lower respiratory tract infections. The appropriate application of quinolones to enable their long-term effect becomes an important issue for the future. Q: Does community-acquired pneumonia have different predominant pathogens in each region, please ask the experts to answer. The common causative agents of community-acquired pneumonia (CAP) include Streptococcus pneumoniae, atypical pathogens (Mycoplasma, Chlamydia, Legionella), Haemophilus influenzae, and Klebsiella pneumoniae. Domestic data also confirmed that the infection of atypical pathogens in CAP has increased significantly in recent years, and occupies a very important position. Nevertheless, about 50% of CAP patients are still unable to know their causative agents. 1. Pathogenesis of outpatients with CAP For young adults and patients without underlying disease, Streptococcus pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, and Chlamydia pneumoniae are common pathogens; for elderly patients or patients with underlying disease, common pathogens are Streptococcus pneumoniae, Haemophilus influenzae, aerobic Gram-negative bacilli, Staphylococcus aureus, and Cattamora. The incidence of viral infections is reported to vary, with some reports as high as 36%;. 2. Pathogenesis of CAP patients who require hospitalization but do not need to be admitted to the ICU The literature reports that the most common pathogens in CAP patients requiring hospitalization are Streptococcus pneumoniae, Haemophilus influenzae, mixed infections (including anaerobes), aerobic Gram-negative bacilli, Staphylococcus aureus, Mycoplasma pneumoniae, Chlamydia pneumoniae, and respiratory viruses. Several studies have found a high incidence of atypical pneumonia in CAP, mainly Mycoplasma pneumoniae and Chlamydia pneumoniae, and a low incidence of Legionella pneumonia. These atypical pathogens infect up to 40-60% of CAP patients requiring hospitalization;, often as part of a mixed infection. Infection with Gram-negative bacilli is uncommon in patients with CAP, but can occur in up to 10% of patients with CAP requiring hospitalization. It occurs more often in patients with underlying disease. 3. Pathogenesis of critically ill CAP patients requiring ICU admission Although the proportion of Gram-negative bacilli infections in CAP patients requiring ICU admission is increasing, the most common causative agents in these patients are Streptococcus pneumoniae, Legionella and Haemophilus influenzae. Some studies suggest that Staphylococcus aureus is also a common pathogen. Atypical pathogens such as Mycoplasma pneumoniae and Chlamydia pneumoniae can also cause exacerbations in patients. In 50-60% of patients with severe CAP, the pathogen is difficult to identify. It is well known that the composition and drug resistance of the causative agents of infectious diseases such as CAP vary greatly among different countries and regions. The epidemiological distribution of CAP pathogens and antibiotic resistance are not consistent across the vast territory of China, where there are great differences in the natural environment and socioeconomic development, and further research and accumulation of information are needed. Q: What are the similarities and differences between the antimicrobial treatment of AECOPD and CAP? The acute exacerbation of COPD is mostly induced by bacterial infection, so antimicrobial therapy has an important position in the acute exacerbation of COPD. When patients have increased dyspnea, increased sputum and purulent sputum, sensitive antibiotics should be selected as early as possible according to the severity of COPD and the corresponding bacterial stratification, combined with local common pathogenic bacteria types and drug-resistant epidemic characteristics and drug sensitivity. If the initial treatment plan is poor, antibiotics should be adjusted promptly according to bacterial culture and drug sensitivity test results. Usually the main causative organisms in COPD grade I or II patients with exacerbation are mostly Streptococcus pneumoniae, Haemophilus influenzae and Catamorax. In addition to the above common bacteria, enterobacteria, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus may be present in acute exacerbations of grade III (severe) and grade IV (very severe) COPD patients. Appropriate antimicrobial therapy should be used according to the possible distribution of bacteria. Antimicrobial therapy should reduce the bacterial load to the lowest possible level to prolong the interval between acute exacerbations in COPD patients. Long-term application of broad-spectrum antibiotics and glucocorticoids is prone to secondary deep fungal infections. Clinical signs of fungal infections should be closely observed and measures to prevent and treat fungal infections should be taken according to the actual situation. The pathogenic characteristics and stratification principles of CAP have been described previously, and the principles of its antimicrobial treatment should also be combined with the local common pathogenic types of CAP and the epidemiological characteristics of drug resistance and drug sensitivity to select sensitive antibiotics for empirical treatment as early as possible. The treatment plan is poor and antibiotics should be adjusted promptly according to bacterial culture and drug sensitivity test results. The difference in their antimicrobial treatment is that the pathogenesis of the two diseases is different, so the choice of antibiotics should be considered differently.